Spark Therapeutics' $4.8B deal confirmed as biggest-ever VC-backed exit in Philly - Technical.ly Philly

Business

Mar. 1, 2019 1:21 pm

Spark Therapeutics’ $4.8B deal confirmed as biggest-ever VC-backed exit in Philly

Quick update on this week's news: The University City life sciences company's acquisition by Swiss pharma giant Roche is the biggest acquisition ever of a VC-backed company within city limits, per PitchBook and PACT.
Founded in 2013, the UCity company announced its acquisition this week.

Founded in 2013, the UCity company announced its acquisition this week.

(Courtesy photo)

The eye-popping $4.8 billion sticker price on Spark Therapeutics’ acquisition deal with Roche announced on Monday is shaping up to be the largest exit ever within city limits for a venture-backed company, according to data from financial data provider PitchBook and the Philadelphia Alliance for Capital and Technologies (PACT).

“Filtering down to just Philadelphia proper does reveal that Spark Therapeutics, once the deal closes, will be the biggest exit ever for Philly-based venture-backed exits,” the company said in an email, citing data from an upcoming report.

According to the Seattle-based company’s data, the current holder of the largest Philly-proper exit title goes to Avid Radiopharmaceuticals, which in 2010 announced its acquisition by Lilly in a deal valued at up to $800 million.

Founded in 2013, Spark is a publicly traded spinout of Children’s Hospital of Philadelphia (CHOP), which invested $33 million in the company. The Philadelphia Inquirer reports that CHOP stands to reap a total return of $430 million for its minority stake in Spark Therapeutics.

As part of the acquisition deal, the company will remain based out of 3711 Market St., and continue to do business as a standalone Roche company.

“This transaction demonstrates the enormous value that global biotech companies like Roche see in gene therapy, a field in which Philadelphia is the unquestioned leader,” said Saul Behar, senior VP of  advancement and strategic initiatives at the University City Science Center, the West Philly research park where Spark began and grew its operations. “[This] further validates Greater Philadelphia’s status as a biotech hub with a very bright future.”

Spark CEO Jeff Marrazzo said the deep pool of resources from Roche, the company plans to “accelerate the development of more gene therapies for more patients for more diseases and further expedite our vision of a world where no life is limited by genetic disease.”

Advertisement

-30-
CONTRIBUTE TO THE
JOURNALISM FUND

Already a contributor? Sign in here
Connect with companies from the Technical.ly community
New call-to-action

Advertisement

A cell and gene therapy development center is taking 680K square feet at KOP’s Discovery Labs

A new Philly nonprofit connects life science pros to poverty-fighting volunteer opportunities

Philly saw $1.35B in business deals in 2019, with life sciences leading

SPONSORED

Philly

How the history of Linode HQ inspires its employees

Chesterbrook, PA

Deacom

Deacom

Apply Now

Malvern, PA

Vanguard

Developer – Entry-level

Apply Now

Malvern, PA

Vanguard

Data Governance Lead

Apply Now

This rising Philly-made startup is shutting down. Here’s why, in its founder’s words

Philadelphia prayed for a tech unicorn with a household name. Now what?

Here’s what we know about goPuff’s reported $750M SoftBank investment

SPONSORED

Philly

When it comes to diversity, Vanguard puts its money where its mouth is

Philadelphia

Inspire

Senior Software Engineer

Apply Now

Philadelphia

Inspire

Software Engineer

Apply Now

1217 Sansom Street, Philadelphia, PA 19107

Perpay

Director of Merchandising

Apply Now

Sign-up for daily news updates from Technical.ly Philadelphia

Do NOT follow this link or you will be banned from the site!